NRX Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
NRXP$2.36-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
NRX Pharmaceuticals, Inc.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB firm ID. 106) | 104 |
| | |
| Report of Independence Registered Public Accounting Firm (PCAOB firm ID. 185) | 106 |
| | |
| Consolidated Balance Sheets | 108 |
| | |
| Consolidated Statements of Operations and Comprehensive Loss | 109 |
| | |
| Consolidated Statement of Changes in Stockholders’ Equity (Deficit) | 110 |
| | |
| Consolidated Statement of Cash Flows | 111 |
| | |
| Notes to Consolidated Financial Statements | 112 |
| | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.